T-cell epitope vaccine design by immunoinformatics
By Atanas Patronov, Irini A. Doytchinova. Open Biology, 2013
400 citations recorded by the source corpus.
Vaccination is generally considered to be the most effective method of preventing infectious diseases. All vaccinations work by presenting a foreign antigen to the immune system in order to evoke an immune response. The active agent of a vaccine may be intact but inactivated (‘attenuated’) forms of the causative pathogens (bacteria or viruses), or purified components of the pathogen that have been found to be highly immunogenic. The increased understanding of antigen recognition at molecular level has resulted in the development of rationally designed peptide vaccines. The concept of peptide vaccines is based on identification and chemical synthesis of B-cell and T-cell epitopes which are immunodominant and can induce specific immune responses. The accelerating growth of bioinformatics techniques and applications along with the substantial amount of experimental data has given rise to a new field, called immunoinformatics. Immunoinformatics is a branch of bioinformatics dealing with in silico analysis and modelling of immunological data and problems. Different sequence- and structure-based immunoinformatics methods are reviewed in the paper.
Subfields: Biotechnology, Molecular Biology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/cc1b5759b81e5554821ea1e57371edaa546861c7
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- Fundamentals and Methods for T- and B-Cell Epitope Prediction (2017, background): “However, they are seldom used as they are computationally intensive and exhibit lower predictive performance than datadriven methods [14].”
- MHCflurry: open-source class I MHC binding affinity prediction (2017, neutral): “[2] Immunotherapy & Immunoprevention, German Cancer Research Center (DKFZ), Heidelberg, Germany”